MRD Evolving as an Endpoint in Clinical Trials @End_myeloma @uabmedicine

MRD Evolving as an Endpoint in Clinical Trials @End_myeloma @uabmedicine

obr

2 months
3 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham explains how measurement of minimal residual disease (MRD) is evolving as an endpoint in clinical trials.
Up Next Autoplay